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Background. Obesity has been hypothesized to contribute to the aggressiveness of thyroid cancer through the production of
abnormal levels of serum adipokines. Leptin receptor (OB-R) expression has also been documented in papillary thyroid cancer
(PTC). Aim. In this translational study, we analyzed in vitro the effects of leptin on the growth and migration of thyroid cancer
cells (TPC-1 and K1), the molecular mechanisms underlying leptin’s action, and the influence of prolonged leptin exposure on
cell response to a protein kinase inhibitor lenvatinib. The expression levels of OB-R mRNA and protein were also investigated
in vivo in a series of aggressive PTCs divided into two groups based on the presence of the BRAF mutation. Results. In TPC-1
and K1 cells, prolonged treatment with leptin (500 ng/ml for 96 h) resulted in a mild increase in the proliferation (about 20%
over control only in K1 cells, p < 0 05) and in the migration of both cancer cell lines. Immunoblot analysis revealed a slight
increase in the phosphorylation of AKT, but no effect on β-catenin and phospho-ERK expressions. The inhibitory effects of
lenvatinib on the viability of both cell lines were not influenced by the leptin treatment. OB-R transcript (in fresh tissues) and
proteins (in formalin-fixed and paraffin-embedded specimens) were expressed in all PTC tissues examined, with no significant
differences between BRAF-mutated and BRAF-wild-type tumors. Conclusions. These results demonstrate leptin’s role in mildly
increasing the aggressive phenotype of PTC cells but without influencing the action of lenvatinib. Further studies will clarify
whether it is possible to target OB-R, expressed in all aggressive PTCs, as an adjuvant treatment approach for these malignancies.
1. Introduction
While the majority of differentiated thyroid cancers are
responsive to the current surgery/radioiodine treatments,
there are subgroups of tumors which show a more aggres-
sive behavior. In these tumors, which have lost the capac-
ity to concentrate radioiodine, the identification of the
pathogenic mechanism involved in their development and
progression is fundamental in order to individualize
molecular targets for novel therapeutic approaches [1–3].
The strong association between obesity and thyroid cancer
and the well-known oncogenic action of some adipokines
and their respective signaling pathways have suggested that
the abnormal levels of adipokines associated with obesity
may be a risk factor for these aggressive thyroid cancers
[4]. Among adipokines, leptin, a pleiotropic molecule
encoded by the obese gene with a pivotal role in regulating
food intake, energy metabolism and body weight, is also
thought to influence the development of many other
human malignancies [5–7]. Indeed, many studies have
demonstrated leptin’s influence on the expression of cell
cycle modulators, cancer cell proliferation and transforma-
tion, and cell migration and invasion [5–7]. In addition, an
overexpression of leptin and its receptor (OB-R) has been
reported in many cancer types, including thyroid malig-
nancies [5–9]. In this study, we analyzed the effects of
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leptin on two human papillary thyroid cancer (PTC) cell
lines, focusing on the molecular mechanisms underlying
leptin’s effects on cell viability and migration. Moreover,
we checked the influence of prolonged leptin treatment
on cell response to the protein kinase inhibitor (PKI) len-
vatinib. The expression of the OB-R transcript and protein
was also investigated in a series of aggressive PTCs classi-
fied as intermediate/high risk according to the 2015 ATA
criteria [10].
2. Materials and Methods
The study design included in vitro and ex vivo experiments as
described below.
2.1. In Vitro Experiments
2.1.1. Thyroid Cancer Cell Lines. For in vitro experiments,
two human PTC cell lines, K1 and TPC-1, were used. These
cell lines contained the BRAF V600E and RET/PTC1 muta-
tion, respectively [11]. Cells were grown in a DMEMmedium
(Thermo Fisher Scientific Inc., Waltham, MA, USA), supple-
mented with a 10% foetal bovine serum (FBS) (Thermo
Fisher Scientific), penicillin (100 IU/ml), streptomycin
(100mg/ml), and amphotericin B (2.5mg/ml) (Sigma-Al-
drich, Milan, Italy), and maintained at 37°C in a humidified
atmosphere containing 5% CO2. Short tandem repeat profil-
ing was used to authenticate these cell lines. Cultured cells
were treated with 200 or 500 ng/ml of leptin (Sigma-Aldrich)
for 96 h (Leptin), 50μM of lenvatinib (Selleckchem, Auro-
gene Srl, Rome, Italy) (Lenvatinib) for 24 h, or with
500ng/ml of leptin for 96h plus 50μM of lenvatinib for an
additional 24 h (Leptin+Lenvatinib). Untreated cells were
used as a control (ctrl).
2.1.2. Cell Viability and Migration Assay. Cell viability was
analyzed by an MTT assay [12]. Briefly, cells were seeded in
96-well plates at a density of 3 0 × 103 in a medium with
10% FBS. After 24 h, the growth medium was replaced by a
fresh medium containing 0.1% FBS and supplemented with
200 or 500ng/ml leptin (Sigma-Aldrich) for 96 h with or
without 50μM of the PKI lenvatinib (Selleckchem, Auro-
gene) for an additional 24 h. The solubilized product was then
quantified with a microplate spectrophotometer (xMark,
Bio-Rad, Milan, Italy) at a wavelength of 540nm and a refer-
ence wavelength of 690nm. Results are expressed as percent-
ages over untreated cells. For the migration assay, after the
treatment with 200 or 500ng/ml of leptin for 96h, 60 × 103
cells suspended in a serum-free medium containing 1% BSA
were plated in the upper compartments of the Boyden cham-
ber (8μm membranes) (Costar, EuroClone, Milan, Italy). In
the bottom wells, 600μl of the medium containing 10% FBS
was added as a chemotactic agent. After 6 h, migrated cells
were fixed and stained with a Diff-Quick stain (Biomap snc,
Monza, Italy). Migration was quantified by viewing eight sep-
arate fields using a microscope (objective 10x) with an eye-
piece equipped with a counting grid. Results are expressed
as percentages over control.
2.1.3. Immunoblot Analysis. Total proteins were extracted
from K1 and TPC-1 cell lysates as previously described [13].
20μg of proteins was run on a 9% SDS-PAGE gel, transferred
to the PVDF membranes (VWR, Milan, Italy), blocked with
PBS-Triton/milk (PBS 1X, 0.1% Triton, and 5% nonfat dry
milk) for 1 h at room temperature, and incubated overnight
with the following antibodies: anti-β-catenin (1 : 1000) (Cell
Signaling, Danvers, MA, USA), anti-AKT and anti-ERK
(1 : 1000) and anti-phospho-AKT and anti-phospho-ERK
(1 : 500) (Cell Signaling and Santa Cruz, Heidelberg, Ger-
many, respectively), anti-OB-R (1 : 500) (Abcam, Cambridge,
United Kingdom), and anti-GAPDH (1 : 10000) (Thermo
Fisher Scientific). The membranes were washed in PBS-
Triton and incubated with a horseradish peroxidase-
conjugated anti-rabbit or anti-mouse antibody (Transduc-
tion Laboratories, Lexington, KY, USA) in PBS-Triton/milk,
diluted to 1 : 5000, 1 : 10000, 1 : 20000, 1 : 30000, or 1 : 8000.
The proteins were visualized by chemiluminescence using
the Western blot detection system ECL Plus (PerkinElmer,
Monza, Italy).
2.2. Ex Vivo Experiments
2.2.1. Patients and Tissue Specimens. Twenty-three Italian
patients who underwent surgery for PTC from July 2010 to
December 2013 were enrolled in this retrospective study.
The inclusion criteria were as follows: (a) histological diagno-
sis of papillary thyroid cancer, (b) intermediate or high risk
for recurrence according to the “2015 ATA Guidelines for
the Management of Adult Patients with Thyroid Nodules
and Differentiated Thyroid Cancer” [10], and (c) percentage
of tumor cells in tissues used for molecular analysis higher
than 60% after histological review.
After thyroidectomy, samples of thyroid tumor tissues
were collected and immediately frozen. In all samples, BRAF
mutational status was determined by the Sanger sequencing,
as previously described [14]. Clinicobiological features
including sex, age, tumor size and foci, extrathyroidal exten-
sion, lymph node metastases, patient outcome, body mass
index (BMI), and BRAFmutational status have been summa-
rized in Table 1. Fresh-frozen tumor tissues from the 23
selected patients were used for gene expression analysis.
Formalin-fixed and paraffin-embedded (FFPE) tumor tissues
from a selection of 10 patients were analyzed by immunohis-
tochemistry. All patients signed an informed consent form at
“Sapienza” University Hospital of Rome (Italy), and the
study protocol was approved by the local institutional medi-
cal ethics committee.
2.2.2. Real-Time PCR Analysis. TRIzol reagent (Thermo
Fisher Scientific) was used for RNA isolation from tissues.
1μg of total RNA was reverse-transcribed with a High-
Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific), and OB-R expression levels were quantified by
real-time PCR in a 7900HT Fast Real-Time PCR System
(Thermo Fisher Scientific) as previously described [15]. Each
sample was analyzed in triplicate and normalized on ACTB
mRNA content. Predesigned TaqMan Assays (probe and
primer sets) for OB-R (Hs00900242_m1; it recognizes all
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the six OB-R isoforms: NM_001003679.3, NM_001003680.3,
NM_001198687.1, NM_001198688.1, NM_001198689.1,
and NM_002303.5) and ACTB (Hs99999903_m1) were
purchased from Thermo Fisher Scientific. Data analyses
were carried out using SDS 2.4 software (Thermo Fisher
Scientific), and results were determined by the comparative
2−ΔCt method and shown as relative expression normalized
to a calibrator sample group.
2.2.3. Immunohistochemical Analysis. Paraffin-embedded
sections (5μm thick) from 10 patients were dewaxed, rehy-
drated, and treated with a citrate buffer (0.01M, pH 6) to
retrieve epitope. H2O2 was then used to block endogenous
peroxidase activity. Immunodetection was carried out using
an anti-OB-R antibody (1 : 200 dilution) (Cell Signaling,
Danvers), and, after washing, incubation with a biotinylated
goat anti-polyvalent antibody (Detection IHC kit, Abcam)
was performed. Finally, staining was visualized using
3,3-diaminobenzidine tetrahydrochloride (Detection IHC
kit, Abcam). The sections were slightly counterstained with
Mayer hematoxylin (Carlo Erba Reagents S.r.l., Milan, Italy)
and were analyzed using a binocular microscope with a 20x
objective, a digital image capture computer system, and the
software supplied with the microscope.
2.3. Statistical Analysis. Data were analyzed by one-way
ANOVA followed by the Tukey-Kramer multiple compari-
sons test. Student’s t-test was used to evaluate the intergroup
differences. All results are expressed as mean ± standard
deviation (SD) and were considered statistically significant
with p values lower than 0.05. All statistical analyses were
performed using GraphPad Prism version 5.0 statistical soft-
ware (GraphPad Software Inc., San Diego, CA, USA).
3. Results
3.1. Effects of Leptin on Thyroid Cancer Cells In Vitro. We
first analyzed the effects of leptin on K1 and TPC-1 cells. In
both cell lines, similar levels of OB-R were detected by the
immunoblot analysis (Supplementary Figure 1). A prolonged
exposure (96 h) to leptin induced a slight but significant
increase in the cell viability of K1 cells (about 20% over con-
trol, p < 0 05) only using 500ng/ml of this adipokine
(Figure 1(a)). In the same experimental conditions, 500 ng/ml
of leptin enhanced themigration of both PTC cell lines (about
100% and 30% over control in K1 and TPC-1, p < 0 001 and
<0.01, respectively) (Figure 1(b)). To elucidate the molecular
mechanisms of leptin effects on our PTC cells, we analyzed
the phosphorylation levels of ERK and AKT, together with
those of β-catenin. Using immunoblot followed by a densito-
metric analysis (Figures 2(a) and 2(b)), we found that
prolonged exposure to leptin promoted a slight increase in
the phosphorylation of AKT but did not affect β-catenin
and phospho-ERK expressions. We then tested the effects of
prolonged leptin treatment on the action of the PKI lenvati-
nib. As shown in Figure 3, we observed that pretreatment
with leptin did not influence the effects of lenvatinib on the
viability of both K1 and TPC-1.
3.2. Expression of Leptin Receptor in Thyroid Cancer Tissues.
Finally, we investigated the expression of OB-R in an Italian
cohort of aggressive PTCs (Table 1). We found that OB-R
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Figure 1: Effects of leptin on the proliferation and migration
properties of K1 and TPC-1 cells. (a) Cell viability was evaluated by
MTT after 96 h of incubation with 200 or 500 ng/ml leptin. Results
are mean ± SD of three independent experiments performed in
eigthplicate. (b) After 96 h of treatment with 200 or 500 ng/ml
leptin, cells were prepared for migration assays as indicated in
Materials and Methods. After 6 h, filters were stained and
photographed at 10x magnification and cells counted. Differences
were evaluated with Student’s t-test. ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p <
0 001 vs. untreated cells.
Table 1: Clinicobiological features of PTC.
Characteristics Study cohort (n = 23)
Sex: male/female 7/16
Median age at diagnosis, years (range) 45.4 (19-71)
Median tumor size∗, mm (range) 17.3 (7-45)
Tumor foci∗: unifocal/multifocal 18/4
Extrathyroidal extension: no/yes 8/15
Lymph node metastases∗: no/yes 9/13
Outcome: NED/BED-SED∗∗ 9/3
Median BMI, kg/m2 (range)∗∗∗ 25.96 (20.65-32.91)
Mutational status: BRAFmutated/wild type 17/6
∗Data not available for one patient. ∗∗Data not available for eleven patients.
∗∗∗Data not available for nine patients. Abbreviations: BED: biochemical
evidence of disease; BMI: body mass index; NED: not evidence of disease;
SED: structural evidence of disease.
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was expressed in all tumor tissues. As shown in Figure 4(a),
we did not find significant differences between the OB-R
mRNA values detected in the subgroup of tumors carrying
the BRAF V600E mutation, compared with those of PTCs
with wild-type BRAF. The same observation was confirmed
by the immunohistochemical analysis of the OB-R protein
expression (Figure 4(b)).
4. Discussion
The search for novel molecular targets in aggressive DTCs
unresponsive to current treatments and recent reports on
the role of leptin and OB-R in some malignancies prompted
us to investigate the possibility of targeting OB-Rs in thyroid
cancer. Thus, in the present study, the role of prolonged lep-
tin exposure in tumor progression and/or expansion, as it
may occur in vivo in TC patients with high BMIs, was first
analyzed in two PTC-derived cell lines carrying RET/PTC1
(TPC-1) and BRAF (K1) mutations which both express
OB-R. We found that prolonged treatment with high doses
of leptin, as it may be observed only in obese individuals,
slightly stimulated the proliferation of only K1 cells, whereas
a significant increase in migration was observed in both cell
lines in the same experimental conditions. The differences in
the mutation drivers may explain the different behavior of
our PTC cells; however, such findings demonstrate that lep-
tin mildly increases the aggressive phenotype of these cancer
cells, which is in line with some previous studies on tumor
cells of thyroid [16] and breast origin [17]. The molecular
mechanism underlying leptin effects was investigated by
focusing on the two main oncogenic pathways activated in
thyroid tumorigenesis [18, 19] through the measurement
of phospho-ERK and phospho-AKT expressions. Our find-
ings demonstrated the involvement of AKT phosphoryla-
tion, with no effects on the expression of phospho-ERK.
Also, expression of β-catenin, whose elevated levels have
recently been associated with TC recurrence [20], was not
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Figure 3: Effects of leptin on the treatment with lenvatinib on K1
and TPC-1 cells. After 96 h of treatment with 500 ng/ml leptin,
selected cells were incubated or not with 50μM lenvatinib for 24 h
and viability was evaluated by an MTT assay. Results are mean ±
SD of three independent experiments performed in eigthplicate.
Statistical analysis was performed using the one-way ANOVA test.
∗p < 0 05, ∗∗∗p < 0 001 vs. untreated cells (indicated as ctrl). ns:
not significant.
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Figure 2: Effects of leptin treatment on signaling pathways of K1 and TPC-1 cells. (a) Immunoblot analysis of β-catenin, phosphorylated
AKT (p-AKT) and AKT, and phosphorylated ERK (p-ERK) and ERK in K1 and TPC-1 cells after leptin treatment. GAPDH was used as a
loading control. Experiments were performed as described in Materials and Methods. (b) Densitometric analysis from a representative
immunoblot of p-AKT/AKT, p-ERK/ERK, and β-catenin. Values are expressed as a ratio over the loading control (arbitrarily assigned as 1).
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modified by treating the cells with leptin. A reduction in the
AKT-mediated pathway has also been described by Uddin
et al. and Cheng et al. by using different exposure times
and concentrations, and, in some cases, even different thy-
roid cancer cell lines [9, 16]. In the latter study, ERK phos-
phorylation was affected after 15min of leptin treatment,
an experimental condition which differs greatly from the
prolonged leptin treatment performed in our study.
Another important finding of our study is the potential
influence of prolonged exposure to high levels of leptin on
the action of lenvatinib, a PKI approved for the treatment
of radioiodine refractory thyroid cancer [21] which has also
been shown to block the proliferation of some thyroid cancer
cell lines in vitro [22]. Interestingly, the effects of lenvatinib
on the viability of both K1 and TPC-1 cell lines were not
modified by pretreatment with leptin. At present, an associa-
tion between high BMI or leptin serum levels and resistance
or intolerance to lenvatinib has never been investigated.
However, it cannot be excluded that a complete inhibition
of leptin-induced effects on thyroid cancer cells may increase
the effects of PKIs and thus decrease the dosage needed to be
effective. As a subsequent step, various compounds able to
block OB-R [17, 23] could be investigated together with PKIs
as a novel therapeutic approach for radioiodine-refractory
thyroid cancer.
Finally, we investigated the expression of OB-R in an Ital-
ian cohort of selected aggressive PTCs classified as interme-
diate or high risk according to the ATA criteria, and all
expressed high levels of fibronectin [24]. We found that
OB-R were expressed in all tumor tissues. However, no sig-
nificant correlation was found between OB-R expression
levels and BMI values, the presence of lymph node metasta-
ses, or patient outcome (data not shown). These results con-
firm those of Zhang et al., which were obtained with a larger
series of patients [25]. In addition, we did not find significant
differences between OB-R mRNA and protein levels in the
subgroup of PTC tumors carrying the BRAF V600E muta-
tion, proposed as a hallmark of tumor aggressiveness [26,
27], and PTCs with wild-type BRAF. Although Uddin et al.
demonstrated that OB-R levels cannot be considered an
independent prognostic marker to predict patient survival
[4], the detection of OB-R in all aggressive PTCs in the pres-
ent study suggests a possible contribution of high levels of
leptin to the progression of thyroid malignancy and a poten-
tial use of OB-R as a therapeutic target for residual or recur-
rent lesions. Further studies which include PTC patients with
other driver mutations which activate additional signaling
pathways, as well as the investigation of the combinatory
effects with other metabolic hormones, may help to shed
more light on the role of this metabolic marker on PTC.
In conclusion, in our experimental conditions, pro-
longed exposure to high concentration of leptin seems to
contribute mildly to increasing the aggressive phenotype of
PTC cells but without influencing the action of lenvatinib.
However, the expression of OB-R in aggressive PTCs sug-
gests their use as a possible target in an adjuvant approach
for thyroid cancer.
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Supplementary Materials
Supplementary Figure 1: expression of leptin receptor
protein in K1 and TPC-1 cells. Immunoblot and densito-
metric analysis of OB-R in K1 and TPC-1 cells. GAPDH
was used as a loading control. Values are expressed as a
ratio over the loading control (arbitrarily assigned as 1).
(Supplementary Materials)
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